News
  • Chemistry of Lipid Nanoparticles for RNA Delivery
    Chemistry of Lipid Nanoparticles for RNA Delivery 2025-07-08
    Review Acc Chem Res. 2022 Jan 4;55(1):2-12. doi: 10.1021/acs.accounts.1c00544. Epub 2021 Dec 1. Chemistry of Lipid Nanoparticles for RNA Delivery Abstract Lipid nanoparticles (LNPs) are a type of lipid vesicles that possess a homogeneous lipid core. These vesicles are widely used in small-molecule drug and nucleic acid delivery and recently gained much attention because of their remarkable success as a delivery platform for COVID-19 mRNA vaccines. Nonetheless, the utility of transient protein expression induced by mRNA extends far beyond vaccines against infectious diseases─they also hold promise as cancer vaccines, protein replacement therapies, and gene editing components for rare genetic diseases. However, naked mRNA is inherently unstable and prone to rapid degradation by nucleases and self-hydrolysis. Encapsulation of mRNA within LNPs protects mRNA from extracellular ribonucleases and assists with intracellular mRNA delivery.In this Account, we discuss the core features of LNPs for RNA delivery. We focus our attention on LNPs designed to deliver mRNA; however, we also include examples of siRNA-LNP delivery where appropriate to highlight the commonalities and the dissimilarities due to the nucleic acid structure. First, we introduce the concept of LNPs, the advantages and disadvantages of utilizing nucleic acids as therapeutic agents, and the general reasoning behind the molecular makeup of LNPs. We also briefly highlight the most recent clinical successes of LNP-based nucleic acid therapies. Second, we describe the theory and methods of LNP self-assembly. The common idea behind all of the preparation methods is inducing electrostatic interactions between the nucleic acid and charged lipids and promoting nanoparticle growth via hydrophobic interactions. Third, we break down the LNP composition with special attention to the fundamental properties and purposes of each component. This includes the identified molecular design criteria, commercial sourcing, impact on intracellular trafficking, and contribution to the properties of LNPs. One of the key components of LNPs is ionizable lipids, which initiate electrostatic binding with endosomal membranes and facilitate cytosolic release; however, the roles of other lipid components should not be disregarded, as they are associated with stability, clearance, and distribution of LNPs. Fourth, we review the attributes of LNP constructs as a whole that can heavily influence RNA delivery. These attributes are LNP size, charge, internal structure, lipid packing, lipid membrane hydration, stability, and affinity toward biomacromolecules. We also discuss the specific techniques used to examine these attributes and how they can be adjusted. Finally, we offer our perspective on the future of RNA therapies and some questions that remain in the realm of LNP formulation and optimization. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: ...
    View More
  • Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies
    Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies 2025-07-04
    Review Research (Wash D C). 2024 Jun 18:7:0370. doi: 10.34133/research.0370. eCollection 2024. Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies Abstract Messenger RNA (mRNA) has emerged as an innovative therapeutic modality, offering promising avenues for the prevention and treatment of a variety of diseases. The tremendous success of mRNA vaccines in effectively combatting coronavirus disease 2019 (COVID-19) evidences the unlimited medical and therapeutic potential of mRNA technology. Overcoming challenges related to mRNA stability, immunogenicity, and precision targeting has been made possible by recent advancements in lipid nanoparticles (LNPs). This review summarizes state-of-the-art LNP-mRNA-based therapeutics, including their structure, material compositions, design guidelines, and screening principles. Additionally, we highlight current preclinical and clinical trends in LNP-mRNA therapeutics in a broad range of treatments in ophthalmological conditions, cancer immunotherapy, gene editing, and rare-disease medicine. Particular attention is given to the translation and evolution of LNP-mRNA vaccines into a broader spectrum of therapeutics. We explore concerns in the aspects of inadequate extrahepatic targeting efficacy, elevated doses, safety concerns, and challenges of large-scale production procedures. This discussion may offer insights and perspectives on near- and long-term clinical development prospects for LNP-mRNA therapeutics. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com
    View More
  • Focused ultrasound/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain
    Focused ultrasound/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain 2025-07-01
    J Control Release. 2022 Aug:348:34-41. doi: 10.1016/j.jconrel.2022.05.042. Epub 2022 Jun 1. Focused ultrasound/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain Abstract Messenger RNA (mRNA) medicine has become a new therapeutic approach owing to the progress in mRNA delivery technology, especially with lipid nanoparticles (LNP). However, mRNA encapsulated-LNP (mRNA-LNP) cannot spontaneously cross the blood-brain barrier (BBB) which prevents the expression of foreign proteins in the brain. Microbubble-assisted focused ultrasound (FUS) BBB opening is an emerging technology that can transiently enhance BBB permeability. In this study, FUS/microbubble-assisted BBB opening was investigated for the intravenous delivery of mRNA-LNP to the brain. The intensity of FUS irradiation was optimized to 1.5 kW/cm2, at which BBB opening occurred efficiently without hemorrhage or edema. Exogenous protein (luciferase) expression by mRNA-LNP, specifically at the FUS-irradiated side of the brain, occurred only when FUS and microbubbles were applied. This exogenous protein expression was faster but shorter than that of plasmid DNA delivery. Furthermore, foreign protein expression was observed in the microglia, along with CD31-positive endothelial cells, whereas no expression was observed in astrocytes or neurons. These results support the addition of mRNA-LNP to the lineup of nanoparticles delivered by BBB opening. Keywords: Blood-brain barrier (BBB); Focused ultrasound (FUS); Lipid nanoparticles (LNP); Messenger RNA (mRNA); Microbubble. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com
    View More
  • SINOEPG's invitation | CPHI China 2025
    SINOEPG's invitation | CPHI China 2025 June 6,2025.
    Join Us at CPHI China 2025! SINOPEG's booth no. W4F66 Exciting news! CPHI China 2025 is just around the corner, taking place June 24–26 at the Shanghai New International Expo Centre. SINOPEG will be showcasing cutting-edge drug delivery system (DDS) solutions at Booth W4F66. As your trusted partner in specialty chemicals and advanced drug delivery systems, we’re eager to share innovations that drive industry progress. Why visit us? Explore our latest portfolio of PEG derivatives, lipids, and custom synthesis services Discuss tailored solutions for your R&D and manufacturing challenges Connect face-to-face with our technical experts We warmly welcome friends, partners, and industry peers from around the globe to drop by! Let’s collaborate to shape the future of pharma.  Dates: June 24–26, 2025 Venue: Shanghai New International Expo Centre Our Booth: W4F66 (Hall W4) Ready to meet? Simply stop by! 
    View More
  • SINOEPG's invitation | TIDES USA 2025
    SINOEPG's invitation | TIDES USA 2025 May 19,2025.
    Monday Motivation: Let's Kickstart TIDES USA 2025! The wait is almost over—TIDES USA 2025 begins! As the leading event for oligonucleotide and peptide innovation, this is the place to connect with industry pioneers and explore breakthroughs shaping the future of therapeutics. SINOPEG is excited to join the conversation at Booth #613! Whether you're looking to discuss cutting-edge PEGylation technologies, lipid technologies, explore customized solutions, or simply network with our team, we're here to collaborate and inspire. Why stop by? Discover our latest advancements in drug delivery systems. Connect with experts driving precision and innovation. Explore partnerships to accelerate your next-gen therapies. Pro tip: Book a meeting with us in advance or drop by anytime—we'd love to brainstorm how we can support your goals! Let's make this week transformative. See you at Booth #613! https://lnkd.in/gpSNd5si #TIDESUSA2025 #Oligonucleotides #PeptideTherapeutics #DrugDelivery #PEGylation #SINOPEG #InnovationInHealthcare
    View More
  • Join Us at TIDES USA 2025 in San Diego! Booth #613
    Join Us at TIDES USA 2025 in San Diego! Booth #613 April 11,2025.
    Join Us at TIDES USA 2025 in San Diego! Mark your calendars! TIDES USA 2025—the premier event for oligonucleotide and peptide therapeutics—is coming to San Diego, USA, on May 19, 2025. Visit SINOPEG at Booth #613 to explore cutting-edge solutions in: Custom PEG Derivatives (mPEG, heterobifunctional PEGs, branched PEGs) Lipid Nanoparticles (LNPs) & Lipidoids for nucleic acid delivery Innovative Linker Technologies & ADC Payloads Why Stop By? Discuss your formulation challenges with our PEGylation experts Discover high-purity excipients for mRNA, siRNA, and peptide therapies Learn how our GMP-grade materials accelerate preclinical-to-commercial transitions Spotlight Case Study: Ask us about our role in developing temperature-stable LNP formulations for a global COVID-19 vaccine partner! Schedule a 1:1 Meeting: Avoid the crowds—reserve your private session today: sales@sinopeg.com Can't attend? Explore our solutions online: http://www.sinopeg.com Let's shape the future of oligonucleotide and peptide therapeutics together! See you at #613. #TIDES2025 DrugDiscovery #LNPs #mRNA #PeptideTherapeutics #BiotechInnovation
    View More
  • SINOEPG's invitation | TIDES USA 2025
    SINOEPG's invitation | TIDES USA 2025 March 31,2025.
    Exciting Announcement! SINOPEG is thrilled to announce that we will be exhibiting at TIDES USA 2025, taking place May 19–22 at the Manchester Grand Hyatt San Diego! Join us at Booth #613 to explore how SINOPEG continues to drive innovation in oligonucleotide and peptide therapeutics. As a trusted partner in the industry, we specialize in delivering high-quality building blocks, advanced intermediates, and customized solutions to accelerate your drug discovery and development projects. Why Visit Us? Discover our cutting-edge portfolio of products and services. Discuss collaboration opportunities with our expert team. Learn how we support global partners in overcoming complex R&D challenges. TIDES USA is the premier event for oligonucleotide and peptide therapeutics, and we're eager to connect with industry leaders, researchers, and innovators shaping the future of biopharma. Let's explore synergies and unlock new possibilities together! Save the Date: May 19–22, 2025 Location: Manchester Grand Hyatt San Diego Find Us: Booth #613 Can't wait to meet you there? Drop us a message or comment below – let's start the conversation today!
    View More
  • mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells
    mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells 2025-06-27
    Mol Ther. 2022 Sep 7;30(9):3078-3094.   doi: 10.1016/j.ymthe.2022.07.007.   Epub 2022 Jul 12. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells Abstract mRNA vaccines have recently proved to be highly effective against SARS-CoV-2.   Key to their success is the lipid-based nanoparticle (LNP), which enables efficient mRNA expression and endows the vaccine with adjuvant properties that drive potent antibody responses.   Effective cancer vaccines require long-lived, qualitative CD8 T cell responses instead of antibody responses.   Systemic vaccination appears to be the most effective route, but necessitates adaptation of LNP composition to deliver mRNA to antigen-presenting cells.   Using a design-of-experiments methodology, we tailored mRNA-LNP compositions to achieve high-magnitude tumor-specific CD8 T cell responses within a single round of optimization.   Optimized LNP compositions resulted in enhanced mRNA uptake by multiple splenic immune cell populations.   Type I interferon and phagocytes were found to be essential for the T cell response.   Surprisingly, we also discovered a yet unidentified role of B cells in stimulating the vaccine-elicited CD8 T cell response.   Optimized LNPs displayed a similar, spleen-centered biodistribution profile in non-human primates and did not trigger histopathological changes in liver and spleen, warranting their further assessment in clinical studies.   Taken together, our study clarifies the relationship between nanoparticle composition and their T cell stimulatory capacity and provides novel insights into the underlying mechanisms of effective mRNA-LNP-based antitumor immunotherapy. Keywords: LNP;   cancer;   design-of-experiments methodology;   extrahepatic delivery;   immunotherapy;   mRNA;   vaccination. Excipient for DNA/RNA Delivery Lipid For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com
    View More
first page 1 2 3 4 5 6 7 8 9 10 last page

A total of 30 pages

Copyright © XIAMEN SINOPEG BIOTECH CO., LTD. All Rights Reserved.

Home

Products

News

contact